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Highlights: 
- MScan is a novel promising MUNE method with good reproducibility and clinical potential. 
- MScan and MPS are better at discriminating between ALS patients and healthy controls 
than MUNIX. 
- Only MScan manages to distinguish patients with less certainty of ALS from healthy 
controls. 
Abstract 
Objective: To examine inter- and intra-rater reproducibility and sensitivity to motor unit loss of a 
novel motor unit number estimation (MUNE) method, MScanFit MUNE (MScan), compared to two 
traditional MUNE methods; Multiple point stimulation MUNE (MPS) and Motor Unit Number 
Index (MUNIX).  
Methods: Twenty-two ALS patients and 20 sex- and age-matched healthy controls were included. 
MPS, MUNIX, and MScan were performed twice each by two blinded physicians. Reproducibility 
of MUNE values was assessed by coefficient of variation (CV) and intra class correlation 
coefficient (ICC). Ability to detect motor unit loss was assessed by ROC curves and area under the 
curve (AUC). The times taken for each of the methods were recorded. 
Results: MScan was more reproducible than MPS and MUNIX both between and within operators. 
The mean CV for MScan (12.3%) was significantly lower than for MPS (24.7%) or MUNIX 
(21.5%). All methods had ICC>0.94. MScan and Munix were significantly quicker to perform than 
MPS (6.3m vs. 13.2m). MScan (AUC= 0.930) and MPS (AUC=0.899) were significantly better at 
discriminating between patients and healthy controls than MUNIX (AUC=0.831).  
Conclusions: MScan was more consistent than MPS or MUNIX and better at distinguishing ALS 
patients from healthy subjects. 
Significance: MScan may improve detection and assessment of motor unit loss. 
 
Keywords: Motor unit number estimation; MScanFit; Multiple point stimulation; MUNIX; ALS; 
reproducibility 
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1. Introduction 
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disease characterized by a decline in 
upper and lower motor neurons and a corresponding denervation of muscle fibers. This leads to 
progressive paralysis with a fatal outcome within an average of 3 years after diagnosis of the 
disease. (Couratier, et al. 2016) 
Overall, there is no method that can measure the exact number of motor units. Nerve conduction 
studies and electromyography cannot provide accurate information about the number of motor unit 
loss. Because of collateral sprouting, where healthy axons take over the muscle territory of axons 
that have been lost, compound muscle action potential (CMAP) amplitude does not decrease until 
50% or more of motor units are lost and does not correlate well with the degree of denervation 
(Daube. 2006, McComas, et al. 1971). Similarly, in muscles with denervation, measurement of 
muscle strength does not accurately reflect the number of remaining motor units. Thus a reliable 
method to monitor loss of motor units in ALS is needed to improve diagnostics and as an outcome 
measure in drug trials seeking a treatment of the disease. 
For this reason, several motor unit number estimation (MUNE) methods have been developed as an 
attempt to quantify the number of motor units. The first MUNE method was described in 1971 
(McComas, et al. 1971), and since then MUNE has been of interest to measure lower motor neuron 
loss. In studies already published, MUNE has been found to be useful in diagnosis, follow-up and 
prognosis of many clinical disorders including ALS and also in the evaluation of drug trials 
(Bromberg and Brownell. 2008, Daube, et al. 2000, Gooch, et al. 2014, Doherty and Brown. 1993). 
Most MUNE methods have been based on estimating the size of an average surface-recorded motor 
unit potential (sMUP) and dividing that value into the maximal CMAP. These include incremental 
stimulation (McComas, et al. 1971), multiple point stimulation (Bromberg. 1993, Daube. 1995, 
Porter, et al. 2008)  and spike-triggered averaging (Bromberg. 1993). Other methods have used 
statistical techniques based on the response of the motor unit to a stimulus either with Poisson 
statistics (Lomen-Hoerth and Slawnych. 2003, Henderson, et al. 2007) or Bayesian statistics 
(Ridall, et al. 2006, Nandedkar, et al. 2004). Motor Unit Number Index (MUNIX) is a more recently 
introduced method which uses the surface interference patterns recorded during voluntary 
contractions to infer the average size of surface-recorded motor unit potentials
 
(Nandedkar, et al. 
2010, de Carvalho, et al. 2008, Doherty and Brown. 1993, Uncini and Kuwabara. 2012). However, 
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the mentioned MUNE methods suffer from several limitations including the presence of subjectivity 
in the estimation process, the failure to obtain a representative sample of units or the fact that it is 
taking too long to perform or analyse.   
To overcome these limitations, a new MUNE method was recently developed, `MScanFit MUNE`, 
(MScan) (Bostock. 2016). This method meets the above-mentioned criticisms by fitting a model to 
a detailed stimulus-response curve or 'CMAP scan' (Maathuis, et al. 2012, Visser and Blok. 2009), 
taking into account the threshold variability of all the units, and avoiding subjectivity. The method 
has been found to be accurate (mean absolute error 7%) for simulated data (Bostock. 2016). In a 
previous study, MScan was tested on patients with neurofibromatosis type 2, where it revealed 
denervation and reinnervation in peripheral nerves suggesting that it may be used to quantify and 
monitor disease progression (Farschtschi, et al. 2016). 
The overall objective of this project was to examine the inter-and intra-rater reproducibility and 
sensitivity to motor unit loss of MScan in the assessment of ALS patients and healthy controls, and 
to compare it with two other more traditional MUNE methods, i.e. Multiple point stimulation 
(MPS) MUNE and MUNIX.   
2. Material and Methods 
2.1 Subjects 
Twenty-two patients with ALS or progressive muscular atrophy (PMA) (7 females and 15 males – 
age range 44-83 years, mean 65.3) and 20 healthy sex- and age-matched healthy subjects (7 females 
and 13 males – age range 44-76 years, mean 65.6) were included prospectively in the study between 
December 2015 and June 2016. Fourteen of the patients had just received the diagnosis before 
participating in the project and eight were diagnosed earlier. Mean duration of symptoms was 34 
months (range 3-120 months). Patients were categorized according to the revised El Escorial criteria 
(Brooks, et al. 2000) which were used as a clinical reference standard (Bossuyt, et al. 2015 STARD 
2015). Five of the patients were categorized as definite, five as probable, seven as laboratory 
supported ALS, one as clinically possible and four with PMA with only lower motor neuron signs. 
Patient demographics are summarized in Table 1. Patients were recruited from the departments of 
Neurology and Neurophysiology at Aarhus University Hospital. All subjects gave their written 
consent prior to examinations and the protocol was approved by the Regional Scientific Ethical 
Committee and the Danish Data Protection Agency. 
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Subjects with a history of carpal tunnel syndrome, polyneuropathy or diseases that could induce 
polyneuropathy were excluded. Moreover, patients with too severe atrophy of the abductor pollicis 
brevis muscle to allow for reliable recordings were also excluded. Two patients were excluded 
because of this. 
Patients (n=22) 
Age (years) 65.3 9.98 (44-83) 
Sex  Females (n=7), Males (n=15) 
Duration of symptoms (months) 34.0 33.93 (3-120) 
ALSFRS-R  35.3 10.98 (9-48) 
Region of onset Bulbar (n=3) 
Upper limb (n=11)  
Lower limb (n=8)  
Table 1. Patient demographics. Values expressed as mean  standard deviation. Values in 
parenthesis indicate range. n=number of patients. 
 
2.2 Clinical Examination  
Detailed neurological examination including evaluation of force by manual muscle testing and 
grading according to the MRC scale and deep tendon reflexes were done on all subjects. ALS 
patients were scored by use of revised ALS Functional Rating scale (ALSFRS-R) (Cedarbaum, et 
al. 1999) (Table 1).    
2.3 Electrophysiological Evaluation  
All examinations were carried out at Department of Neurophysiology in Aarhus University. In all 
subjects, an electrophysiological evaluation was performed, which included a motor and sensory 
nerve conduction study and three MUNE methods; MPS, MUNIX and MScan. All three MUNE 
methods were repeated twice each by two blinded physicians (ABJ and HT) in order to evaluate 
inter- and intra-rater reproducibility of the methods. One physician had two years of experience 
with all MUNE methods while the other physician had 2 months of training. Examinations were 
done either on the same day or within a week. For the examinations done on the same day, all 
electrodes were removed and new electrodes were applied for the retest and the physicians took 
turns. The order of the MUNE tests remained the same for each participant: 1) MPS, 2) MUNIX 
and 3) MScan. The final calculation of MUNE values for each of the methods were done after all of 
the examinations of the subject were finished, and cursors for supramaximal CMAPs and sMUPs 
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were placed so that the physicians were blinded both to their own and the other physician’s MUNE 
values. The final calculations of MUNE values were made by one of the physicians (ABJ). The 
exact times taken for each of the three MUNE examinations were recorded.  
The subject’s hand was cleansed with skin prepping gel and alcohol. The skin temperature was held 
between 32 and 36
o
C by a warming lamp. Recordings were made on the thenar muscles on the 
dominant hand in healthy controls and on the least affected side on patients. The active electrode 
was placed over the abductor pollicis brevis muscle (APB) and the reference electrode was placed 
on the interphalangeal joint of the first digit. A ground electrode was placed on the dorsum of the 
hand. Apart from MScan, all electrophysiological examinations were done using an EMG-
equipment Keypoint version 2.11 (Dantec, Skovlunde, Denmark). 
2.4 Nerve conduction studies (NCS)   
Routine motor and sensory nerve conduction studies were performed on the median nerve to 
exclude a carpal tunnel syndrome. Motor NCS was performed by delivering supramaximal 
stimulation at the wrist and the elbow and recording at APB, and sensory NCS was performed by 
delivering supramaximal stimulation at the wrist and recording at the second and third digits.  
2.5 Multiple point stimulation MUNE  (MPS) 
The recordings were made with a stimulus duration of 0.1 ms and a gain of 0.1 mV/division when 
determining SMUP’s and 2 mV/division when determining CMAP. The median nerve CMAP was 
recorded by delivering supramaximal percutaneous stimulation to the wrist by a handheld bipolar 
stimulator. The recording electrode on the APB muscle was moved several times before accepting 
the CMAP with the highest amplitude. The CMAP amplitude was measured from baseline to 
negative peak. The SMUPs were recorded by gradually increasing and decreasing the stimulus 
intensity just enough to produce an all-or-none response.  After recording one SMUP with a 
minimum amplitude of ≥ 25 µV at one position, the stimulation site was moved along the median 
nerve in 1 cm steps and the process repeated 10 times, until 10 different SMUPs had been recorded.  
In patients with less than 10 SMUPs as many as possible were recorded. To calculate the MUNE, 
the supramaximal CMAP amplitude was divided by the average amplitude of the ~10 SMUPs. 
2.6 Motor Unit Number Index (MUNIX)   
The recordings were performed with a 300 ms window and with a stimulus frequency of 1 Hz and 
gain of 0.5 mV/division. A new supramaximal percutaneous stimulation was delivered to the wrist 
by a bipolar stimulator. The CMAP amplitude was measured from baseline to negative peak by 
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keeping the recording electrodes at the same position. Next, the electromyographic surface 
interference pattern (SIP) was recorded during ten voluntary contractions at increasing isometric 
force levels during abduction of digit 1. The examiner provided manual resistance to abduction of 
digit 1 to maintain near isometric conditions as the participant applied an increasing force. During 
the last recordings, there was a pause of 30 seconds between the contractions in order to avoid 
fatigue (Fuglsang-Frederiksen. 2006). Only SIPs with an area above 20 mV/ms were accepted. The 
recordings were exported to an excel file designed to process the raw data to obtain MUNIX values 
(Neuwirth, et al. 2015). 
2.7 MScanFit MUNE (MScan) 
The recordings were made using the TRONDNF recording protocol, which is part of the Qtrac 
software. (Institute of Neurology, University College, London, distributed by Digitimer Ltd at 
www.digitimer.com.) Other equipment used with the set up was a DS5 bipolar stimulator 
(Digitimer Ltd), a HumBug 50 Hz noise eliminator and a D440 amplifier (Digitimer Ltd). To 
eliminate noise and artefacts due to voluntary movement, the fingers were taped together and the 
most relaxing position of the arm was found. A muting box was developed that provided the 
patients with audio feed-back if movement occurred during the recordings. The subjects were asked 
to remain silent and avoid movement during the examination. The stimulus was gradually increased 
manually until supramaximal stimulation was reached. After the responses to 20 supramaximal 
stimuli had been recorded, the stimulus intensity was automatically decreased with a frequency of 2 
Hz in 0.2% steps, from supramaximal stimulation until there was no longer a motor response, when 
a further set of 20 CMAPs was recorded.  The 20 recordings before and 20 recordings after the 
main scan were used to assess the variability of the responses and the baseline noise. The data were 
plotted as a `CMAP scan` or detailed stimulus response curve with the amplitude of the motor 
response on the y-axis and stimulus intensity on the x-axis. In healthy subjects this created a smooth 
S-shaped curve. In ALS patients with a loss of motor units, the curve was shaped as a stair with 
steps as a sign of collateral reinnervation or loss of motor units (Figure 1). The number of motor 
units was estimated offline, using the MScanFit component of the QtracP analysis program. The 
program generated a preliminary model based on the variance and slope of scan points, which was 
used to simulate the recorded CMAP scan. The model was then refined by making serial 
adjustments to minimize the difference between the simulated and recorded CMAP scans (Bostock. 
2016). The off-line analysis is fast and is done automatically including the modelling without 
requirements of making any parameter adjustments. The analysis took less than five min in total. 
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2.8 Statistical analysis 
The inter-and intra-rater reproducibility of MPS, MUNIX and MScan was tested by intraclass 
correlation coefficient (ICC) calculated for absolute agreement and coefficient of variation (CV) as 
defined by the ratio of the standard deviation to the mean of the MUNE values. The Wilcoxon 
signed rank test was used to test if the three methods differed from each other. To evaluate the 
relation between the three MUNE methods and CMAP amplitude, regression analysis was used. A 
Mann-Whitney test was used to compare the absolute MUNE values of each of the MUNE 
methods. Moreover, the MUNE methods and CMAP amplitude were evaluated with a receiver 
operating characteristic (ROC) analysis, by determining the area under the ROC curve (AUC). 
MedCalc provides two methods for estimating P values, both of which make use of the fact that the 
same subjects were used for each test. Pa refers to the method of Delong et al (DeLong, et al. 1988) 
and Pb to the method of Hanley and MacNeil (Hanley and McNeil. 1983). These methods were also 
used to evaluate the differences between the three MUNE methods. Comparisons between the 
methods were done by using a 2-tailed test and comparisons between each of the MUNE methods 
and the corresponding CMAP amplitude by using a 1-tailed test. When making single comparisons, 
P values < 0.05 were considered significant.  In tables where either single or multiple comparisons 
can be made, and a Bonferroni correction may be appropriate, we provide exact P values. QtracP 
was used for the statistical analyses and for generating the figures. 
3. Results 
3.1 Test of MPS, MUNIX and MScan between groups 
A total of 168 recordings were performed for MPS and MScan each corresponding to two 
recordings by two different observers for each subject. For MUNIX, only 164 recordings were 
performed, because in two patients the examinations could not be performed due to too severe 
muscle weakness. The median MUNE values of MPS, MScan and MUNIX in patients and controls 
are summarized in table 2. 
 MPS MSCAN MUNIX 
 (Median ± range from min to max) 
Patients  30.1 (1-143.3) 32.4(1-123.5) 103.1(2-259.8) 
Controls  132.9 (79.8-251.8) 111.1(71.75-166.8) 207.5(98-423.3) 
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P-values 1.9×10
-6 
1.2×10
-6 
0.00026 
Table 2. Comparison of MUNE-values in MPS, MScan and MUNIX in patients and healthy 
subjects. MUNE values are expressed as medians across 4 recordings on each subject (two per 
observer).  
 
The MUNE values were significantly lower in patients compared with controls in both MPS, 
MScan and MUNIX. There was also a significant difference in MUNE values between all three 
methods both for patients and for healthy subjects. (p<0.05).  
Figure 2 shows the distribution of MUNE values for each of the methods in healthy subjects and 
patients divided into grade 1 (clinically definite ALS), grade 2-3 (clinically probable and lab-
supported) and grade 4-5 (clinically possible or PMA) based on the revised El Escorial criteria. In 
MScan, there was a significant difference between all grades of ALS compared to healthy controls. 
In MPS and MUNIX, there was a significant difference between healthy controls and grade 1 and 2-
3 respectively. However, no significant difference was found between grade 4-5 and healthy 
subjects. The ALSFRS-R scores were significantly different for the El Escorial subgroups. Grade 1 
had significantly lower ALSFRS-R scores compared to grade 2-3 (p=0.024) and grade 4-5 (p= 
0.0037). Similarly, grade 2-3 had significantly lower scores than grade 4-5 (p= 0.0041).  
3.2 Reproducibility 
Table 3 summarizes the coefficients of variation (CV) of MUNE values of MPS, MScan and 
MUNIX expressed as means and their corresponding p-values when comparing the methods. The 
CV values are based on two recordings for each observer for each subject. 
MUNE Coefficients of variation (%) 
 (Mean ± SE) (P for Wilcoxon signed rank test) 
 
MPS MSCAN MUNIX 
MPS v 
MSCAN 
MSCAN v 
MUNIX 
MPS v 
MUNIX 
  Intra-rater 14.4 ± 1.5 8.6 ± 1.6 14.7 ± 1.3 0.00042 0.00056 0.35 
  Inter-rater 20.3 ± 1.5 9.7 ± 1.3 16.7 ± 2.3 2.9×10
-6
 0.00067 0.0068 
  Patients 28.5 ± 2.7 14.7 ± 2.7 25.0 ± 4.6 0.00088 0.0030 0.081 
  Controls 20.5 ± 1.6 9.6 ± 1.3 17.9 ± 2.2 0.00071 0.0024 0.14 
  Combined  24.7 ± 1.7 12.3 ± 1.6 21.5 ± 2.6 3.4×10
-6
 3.8×10
-5
 0.031 
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Table 3. Comparison between coefficients of variation across two repeats by two different 
observers.  P values <0.05 are shown in bold. Combined refers to inter- and intra-rater 
measurements on all subjects. 
 
MScan had significantly lower CV values than MPS and MUNIX both with regards to the inter- 
and intra-rater recordings and in patients and healthy controls separately and combined. MUNIX 
had a significantly lower CV than MPS in inter-rater recordings and inter- and intra-rater recordings 
combined. However, there was no significant difference between CV values of MPS and MUNIX in 
the intra-rater recordings and in patients and healthy controls separately.   
 
Figure 3 A illustrates the CV values of MPS, MScan and MUNIX in patients and controls 
separately and combined (patients and controls). Figure 3B illustrates the CV values of MPS, 
MScan and MUNIX in inter-and intra-rater recordings separately and combined based on both 
patients and controls. 
 
Table 4 summarizes the intraclass correlation coefficients (ICC) and the corresponding confidence 
intervals of MPS, MScan and MUNIX for inter- and intra-rater measurements. The ICC values were 
higher for MScan than MPS and MUNIX both between and within operators. 
  Intra class correlation coefficient (ICC) 
 MPS MScan MUNIX 
Inter-rater 0.970(0.906-0.987) 0.993(0.987-0.996) 0.944(0.898-0.970) 
Intra-rater (observer 1) 0.979 (0.961-0.989) 0.983 (0.968-0.991) 0.970 (0.945-0.984) 
Intra-rater (observer 2) 0.980 (0.963-0.989) 0.985(0.972-0.992) 0.974 (0.952-0.986) 
 Table 4. Summary of intra class correlation coefficients (ICC) across two repeats by two different 
observers. Confidence intervals are shown in parentheses. 
 
3.3 Correlations between MPS, MUNIX, MScan and CMAP 
In patients and healthy subjects combined, MScan and MPS values were similar and a strong linear 
correlation was found between them (R
2
=0.962). MUNIX values were higher and less correlated 
with either MScan (R
2
=0.832) or MPS (R
2
=0.891). (figure 4). All correlations were statistically 
significant. In ALS patients only, there was also a strong and significant linear correlation between 
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all methods: MPS and MUNIX (R
2
=0.87), MPS and MScan (R
2
=0.97) and MScan and MUNIX 
(R
2
=0.79). In healthy subjects, weaker correlations were found: MPS and MUNIX (R
2
=0.62), 
MScan and MUNIX (R
2
=0.43) and MPS and MScan (R
2
=0.12). The correlations were all 
significant except for MPS and MScan (p=0.14). 
In patients and healthy subjects combined, there was a strong quadratic correlation between CMAP 
amplitude and MUNIX (R
2
=0.944) (figure 5), indicating that 94% of the variation in MUNIX 
values was accounted for by the variation in CMAP amplitude.  A weaker correlation was found for 
CMAP amplitude and MPS (R
2
=0.801) and CMAP amplitude and MScan (R
2
=0.724). All 
correlations were significant, also for patients and controls separately. 
3.4 Sensitivity and specificity of MPS, MUNIX, MScan and CMAP 
In figure 6, the potential of MPS, MScan, MUNIX and CMAP amplitude to distinguish ALS 
patients from healthy subjects is illustrated in a ROC curve. (MedCalc Statistical Software version 
16.8 (MedCalc Software bvba, Ostend, Belgium; https://www.medcalc.org; 2016). The best cut-off 
MUNE value for distinguishing between healthy controls and patients was 96.5 for MPS, 75.5 for 
MScan and 146.5 for MUNIX. This yielded the following sensitivities and specificities respectively 
for each of the methods: MPS: 90% and 80.7%, MScan: 92.5% and 80.7% and MUNIX: 82.5% and 
69.5%. MUNE methods were compared with their corresponding CMAP amplitude and evaluated 
by the area under the curve (AUC) as a measure of how well they were able to distinguish between 
patients and healthy subjects. MUNIX and CMAP had the same AUC (0.831). Both MPS and 
MScan had an AUC (0.899 and 0.903 respectively) that were significantly higher than their CMAP 
amplitude (0.841 and 0.845 respectively). When comparing MPS and MScan there was no 
significant difference (Pa=0.11 and Pb=0.14). There were significant differences between MPS and 
MUNIX (Pa=0.029 and Pb= 0.0084) and between MScan and MUNIX (Pa=0.0005 and 
Pb=0.0001). 
3.5 Difference in time to perform MPS, MUNIX and MScan 
Table 5 and figure 7 show the difference in recording times between MPS, MScan and MUNIX 
both in patients, in controls, and combined. In all groups the recording time of MPS was 
significantly longer than of MScan and MUNIX. There was no significant difference between 
MScan and MUNIX. When comparing the recording times between the two observers, the 
experienced observer did MPS recordings significantly faster (p<0.001), but there was no 
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significant difference between the two observers’ recording times for MScan (p=0.82) and MUNIX 
(p=0.26).  
MUNE Recording time (min) 
 
(Mean ± SE) 
(P for Wilcoxon signed rank 
test) 
 
MPS MSCAN MUNIX 
MPS v 
MSCAN 
MSCAN 
v 
MUNIX 
MPS v 
MUNIX 
Patients 12.73 ± 0.44 6.08 ± 0.28 5.92 ± 0.23 2.1×10
-5
 0.40 4.8×10
-5
 
Controls 13.79 ± 0.66 6.48 ± 0.29 6.76 ± 0.18 6.5×10
-5
 0.14 7.1×10
-5
 
Combined 13.24 ± 0.39 6.27 ± 0.20 6.34 ± 0.16 1.1×10
-8
 0.27 2.7×10
-8
 
Table 5. Comparison of recording times (min) between MPS, MScan and MUNIX in patients and 
healthy subjects expressed as means across 4 recordings on each subject (two per observer). P 
values <0.05 are shown in bold. 
 
4. Discussion 
This study was the first one to test the reproducibility and clinical utility of MScan in patients with 
ALS. We have shown that the inter-and intra-rater reproducibility of MScan is significantly better 
than that of MPS and MUNIX. MScan was capable of differentiating ALS patients from healthy 
controls in an earlier stage of the disease than MPS and MUNIX. There is no gold standard in 
MUNE methods. However, the very close agreement between MScan and MPS, which are two 
quite different methods, gives confidence in the accuracy of their estimates. 
4.1 Reproducibility 
All methods had excellent reproducibility with ICC values of >0.94. However, the ICC values are 
all high in part because of the wide variation in motor unit loss between the ALS patients.  A more 
relevant measure of reproducibility for drug studies, for example, is CV, since a halving of CV 
implies that only one quarter of the number of patients would be required to detect a difference in 
treatments. The CVs were significantly lower in MScan both for inter-and intra-rater recordings 
respectively (9.7% and 8.6%) compared with MPS (20.3% and 14.4%) and MUNIX (16.7% and 
14.7%). This study was the first one to test MScan on ALS patients. MScan is a novel MUNE 
method, and reproducibility of this method has never been tested before. Several previously 
published papers have evaluated reproducibility of MUNIX. A recent study measured the intra-rater 
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reproducibility in APB in ALS patients and found a CV of 19.4% and an ICC of 0.74. (Boekestein, 
et al. 2012). Another study measured the inter- and intra-rater reproducibility in the ADM muscle of 
ALS patients and healthy controls and found inter-rater CV values of 23.7% in ALS patients and 
17.5% in healthy subjects and intra-rater CV values of 24.0% in patients and 15.3% in healthy 
subjects. (Ahn, et al. 2010) Thus, similar to our study, there was less variability in healthy controls 
than in ALS patients. Another research group found similar inter-rater reproducibility in ALS 
patients (ICC>0.89) and discovered that the variability was slightly larger in APB (CV=20.5%) than 
in ADM (CV=18.4%) (Nandedkar, et al. 2011). This was also seen in a multicentre MUNIX study 
comparing reproducibility of ADM and APB in healthy subjects. This research group found a 
higher inter-rater reproducibility in ADM (ICC=0.68) than in APB (ICC=0.43) but a lower intra-
rater reproducibility in ADM (ICC=0.67) than in APB (ICC=0.75) (Neuwirth, et al. 2011). In our 
study, the participants were examined in the APB muscle where we found better reproducibility 
than some of the studies mentioned above. This may be because we have paid big attention for 
placing the recording electrode on APB muscle and moved the electrode several times to find the 
highest supramaximal CMAP amplitude which is a major determinant of MUNIX values. 
Reproducibility of MPS has also been assessed in previous studies in ALS patients and healthy 
controls (Doherty and Brown. 1993, Felice. 1995). One study measured intra-rater reproducibility in 
ALS patients and healthy subjects combined and found similar results to ours (CV=12.0%). 
(Lomen-Hoerth and Olney. 2000). This was performed in ADM. Another study found a lower intra-
rater CV of 10.4% in healthy subjects using the adapted MPS methods in thenar muscles (Wang and 
Delwaide. 1995). This, however, was only carried out in 10 subjects. 
4.2 Correlations 
We found that overall, MScan provided similar MUNE values to MPS. In patients, we found that 
MPS and MScan were strongly correlated and both were less correlated with MUNIX. In healthy 
subjects, we found weaker correlation between the methods and no correlation between MPS and 
MScan. Numerous previous studies have evaluated correlation of MUNE methods with varying 
results. A recent study compared MPS and MUNIX on patients with inflammatory demyelinating 
polyneuropathy and found a linear correlation in patients but no correlations in healthy subjects 
(Paramanathan, et al. 2016). This was also the case in another study comparing high density MUNE 
with MUNIX in ALS patients and healthy subjects (Boekestein, et al. 2012). Another study 
compared incremental stimulation MUNE with MUNIX in healthy subjects and found no 
correlations (Furtula, et al. 2013). MPS has also been compared to the statistical method in which 
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one study found a correlation in ALS patients and healthy controls (Lomen-Hoerth and Olney. 
2000), and another study did not show a correlation in healthy controls (Blok, et al. 2010). The 
different results across the studies could partly be explained by the fact that the MUNE methods are 
based on different technical and physiological aspects, and the spread of the values vary between 
the methods.  
We found that CMAP amplitude and MUNIX were strongly correlated and the correlations between 
CMAP amplitude and MPS and MScan respectively were weaker. The strong correlation between 
CMAP amplitude and MUNIX has been reported in numerous previous studies, both in healthy 
subjects and in ALS patients (Nandedkar, et al. 2010, Neuwirth, et al. 2011, Furtula, et al. 
2013,Ahn, et al. 2010). Thus our study confirms that MUNIX values depend too much on CMAP 
amplitude to provide useful estimates of motor unit numbers.  
4.3 Sensitivity and specificity as a test for motor unit loss  
All three methods had the ability to distinguish patients from healthy subjects. Only MScan 
managed to distinguish patients with possible ALS and PMA from healthy subjects suggesting that 
the discriminative potential of MScan in ALS patients with less disease certainty is better than the 
two other methods. We found a higher sensitivity for MScan (92.5%) compared to MPS (90%) and 
MUNIX (82.5%) and a higher specificity for MScan and MPS (80.7%) compared to MUNIX 
(69.5%). Another important issue is whether MUNE methods are better than CMAP amplitude in 
discriminating patients from healthy subjects. To our knowledge, the sensitivity of MUNE methods 
has not been compared to CMAP amplitude in previous studies. In our study, ROC curves showed 
that MPS (AUC=0.899) and MScan (AUC=0.930) were significantly better at discriminating 
between patients and healthy subjects than MUNIX and CMAP amplitude. (AUC=0.831). 
However, MUNIX did not differ from CMAP amplitude in distinguishing patients from healthy 
subjects. MScan had the largest AUC suggesting the highest discriminating value, although there 
was no significant difference between MPS and MScan. ROC curves of different MUNE methods 
have been assessed in previous studies. In one study, MUNIX was performed on ALS patients and 
healthy controls and a slightly higher AUC of 0.897 was found compared with the AUC we found. 
(Furtula, et al. 2013). This was measured in ADM and only 13 patients were included. An 
explanation for the higher AUC could be that the recordings were done on the most affected side. 
Moreover, it is not specified how many of the patients had onset in their upper limb. Another study 
comparing MPS and MUNIX on patients with inflammatory demyelinating polyneuropathy did not 
find difference in AUC between the two methods (Paramanathan, et al. 2016). 
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4.4 Recording times 
The recordings times were significantly longer for MPS than MUNIX and MScan, and for MPS it 
was dependent on the experience of the observer. The experienced observer was significantly faster 
than the less experienced observer. This was not the case for MScan and MUNIX. The recording 
times have not been evaluated in previous studies. 
4.5 Limitations 
There were limitations in this study which are important to address. The sample size was small and 
the recruitment of patients was limited to patients who had sufficient physical and mental strength 
to participate. However, this was not different from other similar studies with ALS patients. We did 
the recordings in APB muscle and due to the split hand phenomenon (Kuwabara, et al. 1999, 
Wilbourn. 2000), this muscle can be too atrophic in ALS to allow for MUNE recordings. Because 
of this, we had to exclude two patients from the study. However, MPS and MScan turned out to be 
more applicable to patients with severe muscle weakness and atrophy. In two of the patients 
included in this study MUNIX, which requires voluntary contraction, could not be performed due to 
severe muscle weakness whereas MPS and MScan could be applied. The limitation of severe 
weakness and atrophy could be avoided by choosing ADM. On the other hand, APB is preferable 
because of higher sensitivity than ADM due to the split hand phenomenon. We examined only APB 
muscle on the least affected side and we also included patients with bulbar or lower limb onset who 
had APB MUNE values comparable to healthy subjects. If we had chosen to examine more muscles 
on the most affected side, the sensitivity could probably have been improved. This, however, would 
have been too time consuming in a reproducibility study such as this one, where the examinations 
for each participant lasted for approximately four hours in total, because two observers did the 
recordings twice each. If we had done the recordings on the most affected side, it would have been 
necessary to exclude several of the patients since their most affected side was too atrophic and weak 
to allow for MUNE examinations. Another limitation is that the ALS patients were compared to 
healthy subjects, and we did not address the question of differentiating ALS from ALS-mimicking 
diseases. 
4.6 Conclusion 
In this study, we found that MScan is a method that takes into account most of the limitations that 
have been found in other MUNE methods in previous published studies. We found excellent 
reproducibility both with regards to inter- and intra-rater measurements, and it was quick and easy 
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to perform and did not depend on the experience of the observer. It had the ability to differentiate 
ALS patients from healthy controls in an earlier stage of the disease than MPS and MUNIX. Our 
study suggests that MScan is a method that has the potential to be implemented in the clinic, where 
the ability to detect motor unit loss may be helpful in ALS and other neuromuscular disorders. The 
good reproducibility may enable more efficient assessment of treatments designed to slow or 
prevent motor neurone degeneration. More and larger studies are needed in order to evaluate 
whether our findings can be reproduced and to explore the potential of MScan as a follow-up tool. 
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Figure 1. Examples of MScan recordings from A: a patient with ALS and B: a healthy subject 
 
Figure 2. Boxplot showing the distribution of MUNE values of MPS, MScan and MUNIX across 
four repetitions in normal controls (NC) and in patients divided into grade 1, grade 2-3 and grade 4-
5. Horizontal line represents the medians and the ends of the boxes the first and third interquartile. 
The whiskers indicate the 10% and 90% interquartile. Comparisons between controls and grade of 
ALS are made. P<0.05 are expressed with *. NS= Not significant. PMA= progressive muscular 
atrophy. Controls are shown in white and patients in striped.   
 
Figure 3. Box plot showing the distribution of coefficients of variations (CV) in A) patients, 
controls and combined (patients and controls) across two repeats by two different observers and B) 
inter-rater, intra-rater and combined (inter-and intra-rater) recordings based on all patients and 
controls. MPS is shown in white, MScan in black and MUNIX in striped. 
 
Figure 4. Linear regression between the three methods (black line). The dashed line indicates the 
line of equality. A. MPS vs MScan. B MUNIX vs MScan. C. MPS vs MUNIX. Patients are shown 
with closed circles and controls with open circles. R
2 
is based on patients and healthy subjects 
combined. 
 
Figure 5. Quadratic regression (black line) between compound muscle action potential (CMAP) 
amplitude and: A. MPS. B. MScan and C. MUNIX. Patients are shown with closed circles and 
controls with open circles. R
2 
is based on patients and healthy subjects combined. 
 
Figure 6. ROC curves comparing area under the curve (AUC) of CMAP amplitude with A. MPS, B. 
MScan and C. MUNIX. Pa is obtained from the method of DeLong et al (1988) and Pb is obtained 
from the method of Hanley and MacNeil (1983). 
 
Figure 7. Box plot showing the distribution of recording times (min) in MPS, MScan and MUNIX. 
MPS is shown in white, MScan in black and MUNIX in striped. 
 
